Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001248618 | SCV001422117 | uncertain significance | not provided | 2022-04-17 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 44 of the MTTP protein (p.Leu44Val). This variant is present in population databases (rs779068565, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with MTTP-related conditions. ClinVar contains an entry for this variant (Variation ID: 972557). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV001248618 | SCV001714118 | uncertain significance | not provided | 2021-02-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004649544 | SCV005146739 | uncertain significance | Inborn genetic diseases | 2024-05-23 | criteria provided, single submitter | clinical testing | The c.130C>G (p.L44V) alteration is located in exon 3 (coding exon 2) of the MTTP gene. This alteration results from a C to G substitution at nucleotide position 130, causing the leucine (L) at amino acid position 44 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Clinical Genetics, |
RCV001248618 | SCV001925353 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001248618 | SCV001970936 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Natera, |
RCV001830046 | SCV002082403 | uncertain significance | Abetalipoproteinaemia | 2020-02-26 | no assertion criteria provided | clinical testing |